XML 33 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration and Other Agreements - Incyte (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2017
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
performance_obligation
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Collaboration And Other Agreements [Line Items]            
Revenues   $ 20,798   $ 1,663 $ 44,327 $ 5,383
Incyte Corporation | Incyte MGA012 Agreement            
Collaboration And Other Agreements [Line Items]            
Non-refundable upfront payment     $ 150,000      
Potential development and regulatory milestone payments under agreement $ 420,000          
Development and regulatory milestones recognized   10,000     10,000  
Potential commercial milestone payments under agreement 330,000          
Number of performance obligations | performance_obligation     2      
Collaborative agreement transaction price 154,000          
Variable consideration recognized $ 4,000          
Maximum | Incyte Corporation | Incyte MGA012 Agreement            
Collaboration And Other Agreements [Line Items]            
Proceeds from royalties (percent) 24.00%          
Minimum | Incyte Corporation | Incyte MGA012 Agreement            
Collaboration And Other Agreements [Line Items]            
Proceeds from royalties (percent) 15.00%          
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement            
Collaboration And Other Agreements [Line Items]            
Revenues $ 150,000 6,100        
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities            
Collaboration And Other Agreements [Line Items]            
Revenues   10,500     $ 13,600  
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Services            
Collaboration And Other Agreements [Line Items]            
Revenues   $ 16,000